We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · June 29, 2022

Safety and Efficacy of Sutimlimab in Patients With Cold Agglutinin Disease



Additional Info

Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial
Blood 2022 Jun 10;139(23)13-16, A Röth, S Berentsen, W Barcellini, S D'Sa, B Jilma, M Michel, IC Weitz, M Yamaguchi, JI Nishimura, JMI Vos, M Storek, N Wong, P Patel, X Jiang, DS Vagge, M Wardecki, F Shafer, M Lee, CM Broome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading